Recent advances in the treatment of AIDS-related Kaposi's sarcoma

American Journal of Clinical Dermatology

Volumn 3, Issue 7, 2002, Pages 451-462

  Cattelan, A M ^a   Trevenzoli, M ^a   Aversa, S M L ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTIRETROVIRUS AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; FOSCARNET; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INDINAVIR; LAMIVUDINE; METALLOPROTEINASE INHIBITOR; PACLITAXEL; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RITONAVIR; SAQUINAVIR; STAVUDINE; TECOGALAN; THALIDOMIDE; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAOCULAR HEMORRHAGE; KAPOSI SARCOMA; LIVER TOXICITY; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SINUSITIS; SKIN DEFECT;

EID: 0036036662     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203070-00002     Document Type: Review

References (127)

1. HIV/AIDS surveillance report
2. Spectrum of ADS-associated malignant disorders
3. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
4. Kaposi's sarcoma among persons with AIDS: A sexual transmitted infection?
5. The epidemiology of acquired immunodeficiency syndrome and associated tumors in Europe
6. Cancer in Kampala, Uganda, in 1989-1991: Changes in incidence in the era of AIDS
7. Malignant tumors and AIDS
8. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons
9. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults
10. Pulmonary Kaposi's sarcoma: Clinical findings and results of therapy
11. Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome
12. Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome
13. Kaposi's sarcoma in the acquired immunodeficiency syndrome: A proposal for uniform evaluation, response, and staging criteria
14. AIDS-related Kaposi's sarcoma: Prospective validation of the ACTG staging classification
15. Kaposi's sarcoma: A result of the interplay among inflammatory cytokines, angiogenic factors and viral agents
16. Identification and partial characterization of a new human herpesvirus associated with Kaposi's sarcoma
17. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
18. Herpes virus like (KSHV) DNA in various forms of Kaposi's sarcoma and malignant lymphoma
19. RNA expression of the herpesvirus-like agent (KSHV) in various types of Kaposi's sarcoma (KS) lesions
20. Detection of Kaposi's sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma
21. Kaposi's sarcoma associated herpesvirus DNA sequences in prostate tissue and human semen
22. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) DNA in saliva of human immunodeficiency virus-infected men: Clinical and biological correlates
23. Detection of human herpesvirus-8 DNA in Kaposi's sarcoma lesions and peripheral blood of human immunodeficiency virus-positive patients and correlation with serological measurements
24. Seroconversion to antibodies against Kaposi's sarcoma associated herpes virus-related latent nuclear antigens before the development of Kaposi's sarcoma
25. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma: Associated herpesvirus/HHV8 a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma
26. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6
27. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma development
28. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein
29. AIDS-Kaposi's sarcoma derived cell express cytokine with autocrine and paracrine growth effects
30. Clinical overview: Issues in Kaposi's sarcoma therapeutics
31. AIDS-related malignancies
32. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor
33. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir
34. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy
35. Resolution of Kaposi's sarcoma associated with undetectable viral level of human herpes-virus 8 DNA in a patient with AIDS after protease inhibitors therapy
36. Regression of acquired immunodeficiency syndrome related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy
37. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma
38. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma
39. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma
40. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: Biological correlated of clinical outcome
41. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: Biological correlates of clinical outcome
42. Long term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients
43. Kaposi's sarcoma in transplant recipients
44. Interferon and other biological agents for the treatment of Kaposi's sarcoma
45. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma
46. Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma
47. Interferon-alpha with zidovudine: Safety, tolerance, and clinical and virological effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS)
48. Prospective randomized trial of two dose levels of interferon alpha with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network Study
49. Chemo-immunotherapy of advanced AIDS-related Kaposi's sarcoma
50. Intralesional interferon alpha and zidovudine in epidemic Kaposi's sarcoma
51. Single agent and combination chemotherapy of Kaposi's sarcoma in acquired immunodeficiency syndrome
52. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastin
53. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome
54. Failure of mitoxantrone in AIDS-related Kaposi's sarcoma
55. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with acquired deficiency syndrome
56. Phase II study of oral idarubicin in patients with AIDS associated Kaposi's sarcoma
57. Phase 11 study of epirubicin in the treatment of Kaposi's sarcoma and AIDS
58. Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine
59. Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent
60. Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma
61. AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin
62. Weekly doxorubicin in the treatment of patients with AIDS related Kaposi's sarcoma
63. Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma
64. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy
65. Evidence of activity of vinorelbine in patients with previously treated epidemic Kaposi's sarcoma
66. Systemic of AIDS-related Kaposi's sarcoma: Results of a randomized trial
67. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, vincristine (ABV) in AIDS-related Kaposi's sarcoma
68. Pegylated liposomal doxorubicin versus doxombicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of randomized Phase III clinical trial
69. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
70. Potentiation of cytotoxic of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome encapsulated doxorubicin
71. Pharmacokinetics, tumor localization, and safety of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma
72. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
73. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma
74. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin
75. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: Clinical, histological, and cell biological evaluation
76. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma
77. Comparison study of liposomal doxorubicin alone or with bleomycin and vincristine for treatment of advanced AIDS-associated Kaposi's sarcoma: AIDS Clinical Trial Group [protocol 286]
78. Taxol: Mechanisms of action and resistance
79. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
80. The microtubule-affecting drug paclitaxel has antiangiogenic activity
81. A trial of paclitaxel (Taxol) in patients with HIV-associated Kaposi's sarcoma
82. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel
83. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma
84. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma
85. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: A case report study
86. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy
87. A phase I dose escalation and pharmacokinetics study of TNP-470 in AIDS-related Kaposi's sarcoma. (ACTG-215)
88. A phase I study of tecogalan, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi's sarcoma and solid tumor
89. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium
90. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma
91. Activity of thalidomide in AIDS-related Kaposi's sarcoma
92. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: Results of a pilot phase II study
93. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: Results of a sequential non-randomized phase II trial
94. Oral 9-cis retinoic acid in AIDS-related Kaposi's sarcoma: AIDS malignancy consortium study 2002
95. Interim analysis of phase II study (Protocol L1057-280) of panretin capsules for AIDS related Kaposi's sarcoma
96. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi's sarcoma using alitretinoin gel
97. Human chorionic gonadotropin in the treatment of HIV-related Kaposi's sarcoma
98. Phase I study of a preparation of human chirionic gonadotropin given subcutaneously to patients with AIDS-related Kaposi's sarcoma
99. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients
100. Inhibition of development of Kaposi's sarcoma related lesions by a bacterial cell wall complex
101. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma
102. Thalidomide is an inhibitor of angiogenesis
103. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma
104. Vitamin A depletion in HIV infection and AIDS
105. Differentiation of human promyelocitic HL 60 cells by retinoic acid is accompanied by an increase in the intracellular pH
106. Active cancer therapy combining 13-cis-retinoic acid with interferon-α
107. Differentiation therapy for acute promyelocitic leukemia
108. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation
109. Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells
110. Topical treatment of epidemic Kaposi's sarcoma with all trans retinoic acid
111. Phase I/II study of intermittent all trans retinoic acid alone and in combination with interferon-alfa 2a in patients with epidemic Kaposi's sarcoma
112. All trans retinoic acid (ATRA) in the treatment of AIDS-related Kaposi's sarcoma: A phase II Illinois Cancer Center Study
113. A multicenter phase II/III study on ATRAGEN (Tretinoin liposomal) in patients with AIDS-associated Kaposi's sarcoma
114. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone
115. Human chorionic gonodotropin has antitumor activity in AIDS-related Kaposi's sarcoma
116. Relationship of HHV-8 peripheral blood mononuclear cell burden to immunodeficiency, opportunistic infections, response to therapy and stage of Kaposi's sarcoma: First National AIDS Malignancy Conference, Bethesda (MD)
117. Frequency of HHV-8 detection in peripheral blood cells in patients with Kaposi's sarcoma: First National AIDS malignancy Conference, Bethesda (MD)
118. Use of antiherpes drugs and the risk of Kaposi's sarcoma: Data from the Multicenter AIDS Cohort Study
119. Anti-herpesvirus treatment and the risk of Kaposi's sarcoma in HIV infection: Royal Free/Chelsea and Westminster Hospitals Collaborative Group
120. AIDS-associated Kaposi's sarcoma
121. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation
122. Human herpesvirus-8 and Kaposi's sarcoma: Relationship with the multistep concept of tumorgenesis
123. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: Formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures
124. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs
125. Matrix metalloproteinase inhibition: A review of anti-tumor activity
126. Block of AIDS-Kaposi's sarcoma cell growth, angiogenesis and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor: A novel strategy for the therapy of KS